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Abstract
Background: A phase II study was performed to investigate the safety and efficacy of weekly doses of combined
paclitaxel and 5-fluorouracil (5-FU) with concurrent radiation therapy, followed by 2 cycles of consolidation
chemotherapy to treat patients with advanced oesophageal carcinoma.
Methods: The eligibility criteria included local, advanced, newly diagnosed and postoperative local regional lymph
node metastasis; an Eastern Cooperative Oncology Group (ECOG) score of ≤ 2; and adequate organ function.
Patients received chemoradiotherapy consisting of radiotherapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) and concurrent
paclitaxel (50 mg/m2) and 5-FU (300 mg/m2) for 96 h on days 1, 8, 15, 22, and 29. The two-cycle consolidation
chemotherapy protocol included paclitaxel (175 mg/m2) plus continuously infused 5-FU (1800 mg/m2) for 72 h
administered on days 57 and 85, after concurrent chemoradiotherapy.
Results: Between February 2012 and August 2013, 53 patients with oesophageal carcinoma were enrolled in the
study. Among these patients, 33 (62.2%) were newly diagnosed and 20 (37.7%) had postoperative local regional
lymph node metastasis. The median overall survival (OS) time was 17.9 months (95% CIs = 11.9-23.9), and the
median progression-free survival (PFS) time was 12.4 months (95% CIs = 8.6-16.1). Approximately 84.9% (45/53) and
50.9% (27/53) of the patients completed ≥ 5 cycles and all 7 cycles of chemotherapy, respectively. Approximately
86.7% (46/53) of patients completed radiation therapy. The 1-, 2-, and 3-year OS rates were 66.0%, 37.7%, and
35.8%, respectively. The 1-, 2-, and 3-year local control rates were 76.9%, 66.4%, and 66.4%, respectively. Seventeen
patients (32%) experienced grade 3 or higher toxicity. Grade 3 to 5 toxicity during chemoradiotherapy included
neutropaenia (7.5%), thrombocytopaenia (1.8%), fatigue (7.5%), anaemia (1.8%), dermatitis radiation (1.8%),
pneumonitis (5.6%), oesophagitis (9.4%) and vomiting (3.7%).
Conclusions: The combination of weekly doses of paclitaxel and 5-FU was well tolerated and produced comparable
results among patients with locally advanced oesophageal cancer. A randomised phase III trial (NCT01591135)
comparing paclitaxel plus 5-FU with cisplatin plus 5-FU is on-going at our hospital.
Keywords: Oesophageal carcinoma, Paclitaxel, 5-Fluorouracil, Chemoradiotherapy
* Correspondence: kuaile_z@sina.com
1Department of Radiation Oncology, Fudan University, Shanghai Cancer
Center, 270 Dong’An Road, Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University,
Shanghai, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Xia et al. Radiation Oncology  (2017) 12:47 
DOI 10.1186/s13014-017-0785-0
Background
Oesophageal cancer is the fifth most common type of
cancer and fourth most common cause of cancer-related
death in China. This cancer is highly malignant because
of high rates of local recurrence and metastasis. Defini-
tive concurrent chemoradiotherapy is the standard treat-
ment for non-surgery patients with oesophageal cancer,
and the use of cisplatin with 5-fluorouracil (PF) is the
most common chemotherapy regimen [1]. However, 5-
year survival rates are poor (26%) following definitive
chemoradiation therapy [2]. Thus, more sensitive, less
toxic chemotherapy regimens are urgently needed.
Paclitaxel is a promising agent with regard to oesophageal
cancer, with response rates of approximately 32% via
single-drug treatment in locally advanced and metastatic
patients [3]. Paclitaxel is a mitotic inhibitor that blocks cells
during the G2M-phase of the cell cycle (i.e., the most radio-
sensitive phase), with a sensitising enhancement ratio of
1.48 [4]. The combination of paclitaxel and cisplatin (TP) is
the most commonly used regimen, and the response rates
among advanced and metastatic patients with oesophageal
cancer are approximately 46%–59% [5–7], with a median
survival of 6.9 to 13 months [5, 6, 8]. Radiotherapy concur-
rent with a monthly schedule of TP resulted in 3-year over-
all survival (OS) and local failure rates of 41% and 27.6%
but a relatively higher haematological toxicity, resulting in
neutropaenia grades 3 and 4 in 30.3% and 31.6% of cases,
respectively [9]. Increased toxicity with no improvement in
OS compared with the PF regimen was associated with the
TP regimen for advanced oesophageal cancer [10].
The investigation of a new paclitaxel-based regimen
and administration route is important for improving
survival and reducing side effects. Effective and well-
tolerated chemotherapy can prolong OS and improve
quality of life. A pilot study of concurrent paclitaxel and
5-FU plus radiotherapy was developed for patients with
localised oesophageal cancer at the University of Texas
MD Anderson Cancer Center [11]. In that study, the
continuous infusion of 5-FU and paclitaxel combined
with radiotherapy 5 times was well tolerated; toxicities
included mild vomiting, nausea, oesophagitis, and ab-
dominal pain. The combination of paclitaxel and 5-FU
was tolerated and effective. Based on these data, we
began a phase II feasibility study to evaluate the failure-
free local control rate, OS, and toxicities in patients with




The eligibility criteria for the study were as follows:
(1) age ≤ 75 years; (2) Eastern Cooperative Oncology
Group (ECOG) score 0–2; (3) cytologically or histo-
logically confirmed oesophageal cancer; and (4) locally
advanced, newly diagnosed patients with T2-4NxM0-
1a or TxNxM1b (supraclavicular lymph node metasta-
ses for middle and lower thoracic oesophageal cancer
or mediastinal lymph node metastases for cervical
oesophageal cancer without organ metastases accord-
ing to the 6th edition of UICC) or postoperative pa-
tients with local regional lymph node metastasis who
did not receive chemotherapy or radiotherapy. Lymph
nodes found via imaging increased gradually over the
follow-up period, and the diameters of these nodes
were more than 1 cm. This sign was considered to in-
dicate postoperative lymph node relapse. Not all pa-
tients required a PET scan.
Patients were required to meet the following labora-
tory criteria: adequate bone marrow function (neutrophil
count > 2.0*109/L, white blood cell count > 4.0*109/L,
and platelet count > 100*109/L), normal renal function,
and normal liver function. Patients with tracheoesopha-
geal fistula, organ metastasis, or complete obstruction
were not eligible for this study. All patients underwent a
complete examination and nutritional assessments. The
disease evaluation included an upper endoscopy, chest
and abdominal computed tomography (CT), ultrasonog-
raphy, and barium oesophagram examination to elimin-
ate distant organ metastasis.
Ethical Considerations
Written informed consent was obtained from all patients
before pre-study assessments, and the Ethics Committee
of the Cancer Hospital Affiliated to Fudan University
approved the study protocol.
Treatment schedule
The chemotherapy regimen consisted of a combination
of paclitaxel and 5-FU. The treatment modality is illus-
trated in Fig. 1. Concurrent chemotherapy was adminis-
tered from the first day of radiotherapy and included
five cycles of paclitaxel (50 mg/m2) over a 3-h infusion
and continuously infused 5-FU (300 mg/m2) for 96 h on
days 1, 8, 15, 22 and 29. Thirty minutes before treatment
with paclitaxel, patients were pre-medicated with 10 mg
of dexamethasone and 300 mg of cimetidine intraven-
ously and 25 mg of promethazine intramuscularly. The
two-cycle consolidation chemotherapy protocol was pac-
litaxel (175 mg/m2) plus continuously infused 5-FU
(1,800 mg/m2) for 72 h on days 57 and 85. The pre-
treatment before paclitaxel treatment was as follows: 25-
mg promethazine intramuscular injection at 0.5 h, 27
tablets of dexamethasone administered orally (0.75 mg/
tablet) at 12 and 6 h before treatment, and 300 mg of
cimetidine administered intravenously at 0.5 h before
paclitaxel treatment. If a grade of ≥ 3 haematological
toxicity occurred and persisted, then chemotherapy was
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suspended until recovery, and the regimen dose was se-
quentially reduced by 25%.
Radiation therapy was administered using 3-dimensional
conformal radiation therapy (3DCRT) or intensity-
modulated radiation therapy (IMRT). Planning was per-
formed using a Megavoltage simulator with a photon en-
ergy of 6 MV. For previously untreated diagnosed patients
and recurrent patients, the gross tumour volume (GTV)
was defined as the volume of the primary tumour ob-
served on the oesophageal barium exam, upper digestive
endoscopy and CT. Metastatic lymph nodes were defined
as lymph nodes ≥ 1 cm in the shortest axis and ≥ 5 mm in
the tracheoesophageal groove. The clinical target volume
(CTV) was defined by adding 3-cm margins of proximally
and distally uninvolved oesophagus without including the
lateral margins and lymph nodes. The planning target
volume (PTV) was calculated by adding 1-cm margins
around the CTV, but the margins were reduced when the
PTV recovered the spinal cord. All patients were treated
with a total dose of either 61.2 Gy in 34 fractions or 50.4
Gy in 28 fractions. The lower dose was used when patients
had abdominal lymph nodes metastasis or tumour in
excess of the limitations of normal organs such as the
lungs, spiral cord, or intestines.
The plan optimisation was as follows: (1) 99% of the
PTV was covered by 95% of the prescribed dose; (2) 95%
of the PTV volume was covered by the prescribed dose;
(3) the maximum dose did not exceed 110% of the pre-
scribed dose in a continuous volume of < 1 cm3 in the
PTV; and (4) the maximum dose of the PTV did not
exceed 110% of the prescribed dose in a continuous vol-
ume of < 1 cm3. The normal tissue constraints of the
critical organs were as follows: a maximum spiral cord
point dose of ≤ 45 Gy; a percentage of total lung volume
receiving ≥ 20 Gy (lung V20) of ≤ 30% and a mean lung
of ≤ 16 Gy, mean heart dose of ≤ 30 Gy, and maximum
intestine dose of ≤ 50 Gy.
Assessment of primary tumour response
The response of the primary tumour was determined 3
months after the last cycle of chemotherapy was com-
pleted. Patients were scheduled to have CT scans and
barium oesophagrams. If no obvious disease progression
or symptoms were present, then the disease was consid-
ered to be controlled. If the disease progressed, then
patients were scheduled to have endoscopy/biopsy, nee-
dle biopsy, or endobroncheal ultrasonography (EBUS).
However, some of the patients who showed disease pro-
gression could not be given a clear pathological diagno-
sis because of the location of the tumour; these patients
were diagnosed via imaging.
Follow up
Over the first year after treatment completion, the pa-
tients returned to the outpatient clinic every 3 months
for a history and clinical examination. During the second
year after treatment, the follow-up assessments occurred
every 6 months and then every year until year 5. When
applicable, disease recurrence, late toxic effects, and
death were documented. Adverse reactions to chemora-
diotherapy were evaluated according to the National
Cancer Institute Common Toxicity Criteria version 3.0
(NCI-CTC 3.0).
Statistical methods
The primary end point of this study was the failure-free
local control rate. The secondary end points included
assessments of safety and compliance, OS, and
progression-free survival (PFS). Local failure was defined
as the recurrence or persistence within the radiation
therapy PTV. Recurrence outside the treatment volume
was defined as distant. OS was calculated from the first
day of chemoradiation therapy to the time of the last
follow-up assessment or death. PFS was defined as the
time from chemoradiotherapy day 1 to progression,
death, or last follow-up assessment. We hypothesised
that the addition of paclitaxel and 5-FU would increase
the failure-free local control rate. A sample size of 53
was required to detect an increase in the local control
rate from 48% to 65% with a power of 80% and a stand-
ard error of 0.05. The data were analysed according to
the intention-to-treat model. Kaplan-Meier curves were
fit to estimate the OS and failure-free local control rates.
Median survival estimates were calculated. Statistical
analyses were performed using SPSS 20.0.
Fig. 1 Treatment schedule
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Results
Patient characteristics
Between February 2012 and August 2013, 53 patients
were enrolled in our study. Figure 2 shows the progres-
sion across the study phases. The baseline characteristics
of the 53 patients are shown in Table 1. The median pa-
tient age was 59 years (range = 42–73). Six patients
(11.3%) had other malignant tumours, and 46 patients
(87.8%) were men. The ECOG performance statuses of
48 and 5 patients were 0–1 and 2, respectively. The most
common tumour histology was squamous (94.3%). Of all
patients, 33 (62.2%) were newly diagnosed, and 20
(37.7%) had postoperative regional lymph node metasta-
sis and had not received prior chemotherapy or radio-
therapy. Of the 33 newly diagnosed patients, 6 (18.1%)
were stage II, 10 (30.3%) were stage III, and 17 (51.5%)
were stage IV. Two had tumours in their cervical re-
gions, 7 had tumours in their upper thoracic regions, 9
had tumours in their middle thoracic regions, 9 had
tumours in their lower thoracic regions, and 6 had
tumours in multiple synchronous primary sites. The me-
dian interval between surgery and relapse concerning
the 20 patients with postoperative lymph node relapse
was 15.2 months. Twenty-one and 32 patients were
treated using IMRT and 3D-CRT, respectively. The me-
dians for GTV and PTV were 55.2 cm2 and 410.7 cm3,
respectively.
Local control and OS rates
The median follow-up time was 38.4 months. At the
time of our analyses, 20 patients were living, and 15
patients showed no evidence of disease progression. The
1-, 2-, and 3-year OS rates were 66.0%, 37.7%, and
35.8%, respectively. The 1-, 2-, 3-year local control rates
were 76.9%, 66.4%, and 66.4%, respectively. The median
OS time was 17.9 months (95% CIs = 11.9-23.9), and the
Fig. 2 Consort diagram of patient progress throughout the study
Table 1 Patient characteristics (N = 53)










Tumor location of newly diagnosed 33 (62.2)
Cervical 2 (3.8)
Upper thoracic 7 (13.2)
Middle thoracic 9 (17.0)
Lower thoracic 9 (17.0)




Stage (UICCb 6th edition)




Postoperative LNMc 20 (37.7)
Planned dose of radiation
61.2 Gy 41 (77.4)
50.4 Gy 12 (22.6)
aEastern Cooperative Oncology Group; bUnion for International Cancer Control;
Clymph node metastasis
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median PFS time was 12.4 months (95% CIs = 8.6-16.1).
The Kaplan-Meier curves for the failure-free local con-
trol rates and OS times are shown in Fig. 3. The 3-year
OS rate was 27.3% for the newly diagnosed group and
50.0% for the postoperative recurrent group, with me-
dian survival times of 16.4 and 21.7 months, respectively
(P = 0.235). The mean OS was 21.4 months for the radi-
ation dose of 61.2 Gy and 12.5 months for the dose of
50.4 Gy (P = 0.011). A total of 38 patients (71.7%)
showed treatment failure. Ten patients showed only
locoregional failure, 22 patients showed only distant me-
tastasis, 4 patients showed concurrent locoregional/dis-
tant failure, and 2 patients failed therapy due to
radiation toxicity. The treatment failure patterns of the
38 patients are presented in Table 2. At the time of the
analysis, 26 patients had distant metastases. The sites of
the metastases included the lungs (14 patients, 26.4%),
bones (10 patients, 18.8%), liver (6 patients, 11.3%), skin
(2 patients, 3.7%), adrenal glands (2 patients, 3.7%), and
distant lymph nodes (12 patients, 22.6%). Of the 14 cases
of locoregional failure, 10 patients showed local/regional
recurrence, and 4 showed persistent local/regional dis-
ease (3 patients did not complete radiotherapy).
Feasibility and toxicity
Of all patients, 41 had a planned radiation dose of 61.2
Gy, and 38 (92.6%) completed radiotherapy treatment.
Of the 12 patients with a planned radiation dose of 50.4
Gy, 8 (66.6%) finished the complete radiotherapy regi-
men. A total of 46 patients (86.7%) completed treatment
based on our definition for completing the radiotherapy
regimen. Seven (13.2%) patients did not finish radiother-
apy because of grade II toxicity to the skin (1 patient),
grade III cough and haemoptysis (1), fever lasting 10
days (1), grade III vomiting (1), obstruction of the
oesophagus (2), or death from gastrointestinal bleeding
(1). A ≥ 5-cycle dose of concurrent chemotherapy com-
bined with paclitaxel and 5-FU during radiotherapy was
administered to 45 patients (84.9%), and a full dose of 7
cycles of chemotherapy was administered to 27 patients
(50.9%). Eight patients (15.1%) did not finish the 5-cycle
dose of concurrent chemotherapy because of obstruction
of the oesophagus (2), disease progression (1), adverse
reactions (4), or death from gastrointestinal bleeding (1).
The gastrointestinal bleeding was considered to be
caused by a tumour.
The toxicity and tolerability of the therapy were evalu-
ated in all patients. The toxicities of chemoradiotherapy
(graded according to NCI-CTC 3.0) are outlined in
Table 3. Seventeen patients (32%) experienced grade 3 or
higher sever events in this study. The most frequent acute
adverse events for grades 3 and 4 were neutropaenia,
oesophagitis, and fatigue. Grades 3 and 4 neutropaenia
were observed in 3 (5.6%) patients and 1 (1.8%) patient,
respectively. Grades 3 and 4 thrombocytopaenia, anaemia,
fatigue, and oesophagitis occurred in 1/53 (1.8%), 1/53
(1.8%), 4/53 (7.5%), and 5/53 (9.4%) cases, respectively.
Eight (15.0%) of the 53 patients experienced fever in
addition to the patients who experienced radiation
pneumonitis. Three of the 8 patients with fever experi-
enced febrile neutropaenia. The other types of adverse re-
actions related to treatment were mild and included
Fig. 3 OS (a) and local control rate (b) curves for all patients
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hypoalbuminaemia, anorexia, hoarseness, and pericardial
effusion. No allergic reaction was recorded in any of
the patients. The grade ≥ 3 pneumonitis and dermatitis
radiation rates were 5.6% (3/53) and 1.8% (1/53), re-
spectively. The 2 treatment-related deaths among the
53 patients were because of radiation pneumonitis.
Three patients showed pericardial effusion without
symptoms. For 2 of these patients, effusion occurred
within 3 months after completing radiotherapy. For the
remaining patient, effusion occurred within 6 months
of completing radiotherapy.
Discussion
In our phase II study, the regimen of concurrent
weekly paclitaxel, 5-FU, and radiotherapy showed
promise for treating advanced oesophageal cancer in
terms of the local control rate, OS, and low rate of
side effects. Seventeen patients (32%) experienced
grade 3 or higher sever events in this study. The com-
mon adverse reactions were bone marrow suppression,
oesophagitis, fatigue, and pneumonitis. The 1- and 3-
year local control rates were 76.9% and 66.4%, respect-
ively. The median OS time was 17.9 months. The 1-
and 3-year OS rates were 66.0% and 35.8%, respect-
ively, although 69.8% (37/53) of the patients in this
study were stage IV and showed recurrence.
Table 3 Treatment toxicitya
Grade 1 2 3 4 5
N = 53 No. (%) No. (%) No. (%) No. (%) No. (%)
Neutropaenia 21 (39.6) 8 (15.0) 3 (5.6) 1 (1.8) 0
Thrombocytopaenia 9 (16.9) 4 (7.5) 1 (1.8) 0 0
Anaemia 21 (39.6) 8 (15.0) 0 1 (1.8) 0
Vomiting 9 (16.9) 3 (5.6) 1 (1.8) 0 0
Feverb 7 (13.2) 1 (1.8) 0 0 0
Fatigue 14 (26.4) 3 (5.6) 3 (5.6) 1 (1.8) 0
Alopecia 9 (16.9) 6 (11.3) 0 0 0
Hypoalbuminaemia 7 (13.2) 2 (3.7) 0 0 0
ALTc 9 (16.9) 3 (5.6) 1 (1.8) 0 0
Anorexia 16 (30.1) 11 (20.7) 1 (1.8) 0 0
Dermatitis radiation 10 (18.8) 5 (9.4) 1 (1.8) 0 0
Oesophagitis 25 (47.1) 16 (30.1) 5 (9.4) 0 0
Hypocalcaemia 6 (11.3) 2 (3.7) 0 0 0
Hypomagnesaemia 1 (1.8) 0 0 0 0
Hyponatraemia 2 (3.7) 0 2 (3.7) 0 0
Hypophosphataemia 3 (5.6) 0 0 0 0
Constipation 2 (3.7) 2 (3.7) 0 0 0
Diarrhea 3 (5.6) 0 0 0 0
Peripheral sensory neuropathy 13 (24.5) 4 (7.5) 0 0 0
Pneumonitis 5 (9.4) 0 1 (1.8) 0 2 (3.7)
Hypokalaemia 3 (5.6) 0 1 (1.8) 0 0
Hoarseness 5 (9.4) 0 0 0 0
Ventricular arrhythmia 1 (1.8) 0 0 0 0
Creatinine increased 1 (1.8) 0 0 0 0
Pericardial effusion 2 (3.7) 0 0 0 0
aToxicity was grade according to the National Cancer Institute Common Toxicity Criteria, version 3.0; bOf the 8 patients, 3 patients experienced febrile
neutropenia; CAlanine aminotransferase increased
Table 2 Patterns of failure
No. Percent
Any failure 38 71.7
Locoregional failure only 10 18.9
Distant failure only 22 41.5
Locoregional plus distant 4 7.5
Toxicity 2 3.7
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Based on the 3-year follow-up results of our study and
compared with other studies of PF concurrent radiother-
apy, the paclitaxel and 5-FU regimen might have
produced less toxicity and increased local control. In the
RTOG 8501 study [2], local disease failure was the great-
est cause of treatment failure and comprised 54% of the
PF combined regimen therapy group. The median sur-
vival duration was 14.1 months with a 5-year survival
rate of 26% in the chemoradiotherapy treatment group.
In addition, grades 3 and 4 adverse reactions occurred in
42% and 4% of the patients, respectively. In the
RTOG9405 study [12], patients were treated with radio-
therapy doses of 64.8 and 50.4 Gy with DDP plus 5-FU,
and the median survival times were 13.0 and 18.1
months, respectively. The incidence of local failure was
56% in the high dose group and 52% in the standard
dose group. The RTOG9405 study was composed of
7.7% T4 patients and 21.5% N1 patients, and the inci-
dences of grade 3 to 5 acute toxicity in the high-dose/
low-dose groups were 76% and 71%, respectively. In our
study, however, all patients had non-resectable or recur-
rent oesophageal cancer, including 17/33 (51.5%) previ-
ously untreated patients diagnosed with stage IV disease.
Ohtsu et al. reported the use of chemoradiotherapy for
oesophageal cancer with T4, M1 lymph node involve-
ment, or both. In this study, the pattern of first failure
was 57.4% (31/54) locoregional and 38.8% (21/54) dis-
tant, and the treatment resulted in a median survival
duration of 9 months with a 3-year survival rate of 23%
[13]. In our study, the median OS was 17.9 months, and
the 1- and 3-year failure-free local control rates were
76.9% and 66.4%, respectively, which represented an im-
provement compared with the results reported in the PF
regimen study.
Paclitaxel and cisplatin (TP) regimens are the most
commonly reported paclitaxel-based regimens. The
grade ≥ 3 haematological toxicity rates of TP are 30.6-
73.7% [5, 9, 14]. In our study, the grade ≥ 3 haemato-
logical toxicity rate was 11.3%, which was lower than the
results reported in a TP-based group study. Adelstein et
al. reported the use of TP in a phase II study [10]. The
median survival was 15 months for patients with stage
T3, N1 or M1 (nodal) oesophageal cancer, which was
lower than that observed in our study. Neutropaenia
(95%) and nausea (95%) were the most frequent grade
III/IV toxicities, and 16 patients (40%) experienced neu-
tropaenic fever, which must be addressed. This toxicity
is significant and was higher than that in our study. Tu
et al. reported a retrospective study of combined-
modality therapy consisting of the TP regimen with a
concurrent IMRT of 60 Gy [14]. The median OS was
18.0 months, and grade 3 haematological and radioder-
matitis toxicities were observed in 11 (30.6%) and 8
(22.2%) patients, respectively. That study was composed
of 66.7% stage II-III patients. By contrast, all patients in
the present study had non-resectable or recurrent
oesophageal cancer, and only 16/53 (30.1%) patients
were stage II-III. Tang et al. reported a phase II study of
concurrent chemoradiotherapy with a 3-week schedule
of TP for oesophageal cancer [9]. The median OS was
28.5 months; however, neutropaenia grade 3-4 occurred
in 61.9% of the patients, with relatively higher haemato-
logical toxicity. In the RTOG 0113 study, one group was
treated with TP and a radiotherapy dose of 50.4 Gy, and
grades 3 and 4 adverse reactions occurred in 43% and
40% of the patients, respectively [15]. However, another
group was treated with paclitaxel and 5-FU and exhib-
ited lower treatment-related mortality and less grade 4
toxicity than a group treated with TP. These results sug-
gest that compared with the cisplatin and 5-FU regimen
containing paclitaxel, the adverse reactions in our study
associated with paclitaxel and 5-FU were relatively low.
The TP regimen might have higher haematological tox-
icity, similar to the results of a previous phase II study
of concurrent chemoradiotherapy with TP for patients
with inoperable oesophageal cancer [9].
The Chemotherapy for Oesophageal Cancer Followed
by Surgery Study (CROSS) showed that neoadjuvant
chemoradiation combined with carboplatin and pacli-
taxel concurrent with radiation significantly prolonged
OS compared with surgery alone. Neoadjuvant chemora-
diotherapy combined with a paclitaxel and carboplatin
regimen did not increase surgery-related mortality.
Thus, preoperative chemotherapy combined with carbo-
platin and paclitaxel followed by surgery should be con-
sidered as a standard of care among patients with
resectable oesophageal cancer. A randomised phase III
trial (NCT02459457) with a larger sample size is cur-
rently examining the efficacy of paclitaxel plus 5-FU
compared with paclitaxel plus carboplatin concurrent
with radiotherapy among patients with local advanced
oesophageal cancer at our hospital.
While undergoing chemoradiotherapy in our study, 8
patients experienced fever, and 3 of these patients expe-
rienced febrile neutropaenia. The rate of fever was
higher than expected and higher than the rates reported
in other studies [9, 16, 17]. We do not have a reasonable
explanation for this discrepancy, and the patient with a
fever caused by pneumonitis without additional symp-
toms was treated with a similar approach as the fever
patients and was not evaluated via chest CT. The grade
5 radiation pneumonitis rate was 3.7% (2/53), which was
higher than that in other studies [9, 17, 18]. The 2 pa-
tients with grade 5 radiation pneumonitis completed
concurrent chemotherapy, and both died within 3
months of undergoing the radiotherapy regimen; one pa-
tient with T4 received 61.2 Gy of radiation therapy, and
the another with M1 received 50.4 Gy of radiotherapy.
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The lung doses associated with the two deaths were
within the normal constraints. The lung V20 and mean
lung dose of the two deaths were 19.1% and 23.4%, 11.6
Gy and 15.2 Gy, respectively. We do not have a reason-
able explanation for this finding, which might be attrib-
utable to the small number of patients or the late stage
of cancer. We believe that the lung dose was only one of
the factors that affected the occurrence of radiation
pneumonia. One study reported that 7% of patients with
late-stage cancer succumbed to treatment-related death
after chemoradiotherapy [13]. Similar to other reports
[19, 20], 84.9% (45/53) of the patients in our study com-
pleted a concurrent chemoradiotherapy regimen. How-
ever, 18 patients did not complete the consolidation
chemotherapy because they were unwilling (5) or experi-
enced disease progression (5) or an adverse reaction (8).
The completion rate of the full dose of 7 cycles of
chemotherapy was lower than previous reports [19, 20].
Compared with patients in the later stages, their toler-
ance was poor.
The limitations of our study are as follows. 1) The
homogeneity of the patients in the group was low; pa-
tients in phases II-III and IV were included, and postop-
erative recurrence was present. 2) The radiation dose
was not uniform. Although the standard radiotherapy
dose is 50.4 Gy in Europe and the United States, the
radiotherapy dose for oesophageal cancer in China is
often 60–70 Gy. Normal tissue could not tolerate the
use of 50.4 Gy in our study. Wang et al. reported that
patients who received a radiation dose of ≥ 50 Gy
showed a better outcome than those who received < 50
Gy [20]. Regarding the limitations of our study, a rando-
mised phase III trial (NCT01591135) with a larger sam-
ple size is currently examining the efficacy of paclitaxel
plus 5-FU compared with cisplatin plus 5-FU with
concurrent radiotherapy employing a unified dose of
61.2 Gy at our hospital. In that study, the patient inclu-
sion criterion was local advanced oesophageal squamous
cell carcinoma (T2N0M0-TxNxM1a, AJCC 2002). Any
patients with exploratory thoractomy, radiotherapy,
chemotherapy or targeting therapy were excluded.
Conclusions
In conclusion, our study indicates that weekly infused
paclitaxel and continuously infused 5-FU for 72 h,
followed by 2-cycle consolidation chemotherapy, is a
promising regimen with good tolerability for patients
with oesophageal cancer. Our study is limited by the
small sample size. A current analysis of the efficacy of
paclitaxel plus 5-FU compared to cisplatin plus 5-FU is
ongoing at our hospital.
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